跳至主要内容
临床试验/NCT04731077
NCT04731077进行中(未招募)不适用

Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the Avenir Complete™ Femoral Stem (Implants and Instrumentation)

Zimmer Biomet18 个研究点 分布在 6 个国家目标入组 275 人开始时间: 2021年9月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Zimmer Biomet
入组人数
275
试验地点
18
主要终点
Survival of the study device; whether or not it is still implanted in the subject

研究概览

简要总结

The main objectives of this study are to confirm the long-term safety, performance and clinical benefits the Avenir Complete femoral stem and its instrumentation when used in primary total, hemi, and revision hip arthroplasty.

详细描述

The main objectives of this study are to confirm the long-term safety, performance and clinical benefits the Avenir Complete™ femoral stem and its instrumentation when used in primary total, hemi, and revision hip arthroplasty:

The primary endpoint is defined by the survival of the implant system at 10 years, which is based on the removal or intended removal of the "study device and determined using Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.

The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is at least 20 years old or older and skeletally mature.
  • Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases;
  • Failed previous hip surgery including
  • Joint reconstruction (osteotomy)
  • Arthrodesis
  • Hemi-arthroplasty or total hip replacement (THR)
  • Acute traumatic fracture of the femoral head or neck;
  • Avascular necrosis of the femoral head.
  • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study;

排除标准

  • Acute, chronic, local, or systemic infections;
  • Severe muscular, neural, or vascular diseases that endanger the limbs involved;
  • Lack of bony structures proximal or distal to the joint, so that good Inclusion criteria
  • Patient is at least 20 years old or older and skeletally mature.
  • Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases;
  • Failed previous hip surgery including
  • Joint reconstruction (osteotomy)
  • Arthrodesis
  • Hemi-arthroplasty or total hip replacement (THR)
  • Acute traumatic fracture of the femoral head or neck;
  • Avascular necrosis of the femoral head.
  • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study;
  • Exclusion criteria
  • Acute, chronic, local, or systemic infections;
  • Severe muscular, neural, or vascular diseases that endanger the limbs involved;
  • Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible;
  • Total or partial absence of the muscular or ligamentous apparatus;
  • Any concomitant diseases that can jeopardize the functioning and the success of the implant;
  • Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel, etc.);
  • Local bone tumors and/or cysts;
  • Pregnancy;
  • Skeletal immaturity.
  • Patients unwilling or unable to give consent, or to comply with the follow-up program;
  • Patients who have any condition that would - in the judgement of the Investigator - place him/her at undue risk or
  • interfere with the study;
  • Any vulnerable subject:
  • a prisoner
  • mentally incompetent or unable to understand what participation in the study entails
  • a known alcohol or drug abuser
  • anticipated to be non-compliant
  • Patients with plans to relocate during the study follow-up period;
  • Individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate;

研究组 & 干预措施

Avenir Complete Femoral Stem

Other

All enrolled subjects receive the study implant

干预措施: Avenir Complete Femoral Stem (Device)

结局指标

主要结局

Survival of the study device; whether or not it is still implanted in the subject

时间窗: 10 years

Survival is classified as removal of the study device for any reason

次要结局

  • Radiographic analysis(10 years)
  • Oxford Hip Score(10 years)
  • Patient Quality of Life(10 years)
  • Incidence of treatment-emergent Adverse Events (safety)(10 years)
  • Harris Hip Score(3 years)

研究者

发起方
Zimmer Biomet
申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验